Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

Philippe Moreau; Meletios A Dimopoulos; Joseph Mıkhael; Kwee Yong; Marcelo Capra; Thierry Façon; Roman Hájek; Ivan Špıčka; Ross Baker; Kihyun Kım; Gracia Martínez; Chang‐Ki Min; Luděk Pour; Xavier Leleu; Albert Oriol; Youngil Koh; Kenshi Suzuki; Marie‐Laure Risse; Gaëlle Asset; Sandrine Macé; Thomas G. Martin; Philippe Moreau; Meletios A Dimopoulos; Joseph Mıkhael; Kwee Yong; Marcelo Capra; Thierry Façon; Roman Hájek; Ivan Špıčka; Ross Baker; Kim Ki‐Hyun; Gracia Martínez; Min Chang‐Ki; Luděk Pour; Xavier Leleu; Albert Oriol; Youngil Koh; Kenshi Suzuki; Tom Martin; Hang Quach; Andrew Lim; Helen Crowther; Hanlon Sia; Cyrille Hulin; Mohamad Mohty; Gábor Mikala; Zsolt Nagy; Marta Reinoso Segura; Laura Rosiñol; Münci Yağcı; Mehmet Turgut; Mamta Garg; Gurdeep Parmar; Brad Augustson; Nelson Castro; Edvan de Queiroz Crusoé; Tomáš Pika; Sosana Delimpasi; Kenichi Ishizawa; Anup George; Т. С. Константинова; Javier de la Rubia; Kim Sung-Hyun; Ângelo Maiolino; Tony Reiman; Richard LeBlanc; Shigeki Ito; Junji Tanaka; А. С. Лучинин; I. V. Kryuchkova; Joaquín Martínez‐López; Jesse Shustik; Lionel Karlin; Argiris Symeonidis; Miklós Egyed; Mario Petrini; Michèle Cavo; Michihiro Uchiyama; Hilary Blacklock; Mutlu Arat; James E. Griffin; Hannah Hunter; Tonda Buck; Αchilles Anagnostopoulos; Κωνσταντίνος Κωνσταντόπουλος; Tamás Masszi; Sara Bringhen; Barbara Gamberi; Yawara Kawano; Kim Jin Seok; Hakan Özdoğu; Fahir Özkalemkaş

doi:10.1016/s0140-6736(21)00592-4

Related publications

Article2020

Isatuximab plus carfilzomib and dexamethasone vs. carfilzomib and dexamethasone in relapsed/refractory multiple myeloma (ikema): interim analysis of a phase 3, randomized, open-label study

Mehmet Turgut, Philippe Moreau, Meletios A Dimopoulos, Joseph Mıkhael, Kwee Yong, Marcelo Capra, Thierry Façon, Roman Hájek, Marie‐Laure Risse, Gaëlle Asset, Sandrine Macé, Thomas G Martin

Article2020

ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (IKEMA): INTERIM ANALYSIS OF A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY

Ângelo Maiolino, Philippe Moreau, Meletios A Dimopoulos, Joseph Mıkhael, K. Yong, Marcelo Capra, Thierry Façon, Roman Hájek, Marie‐Laure Risse, Gaëlle Asset, Sandrine Macé, Thomas G Martin

Article2024

Isatuximab plus carfilzomib–dexamethasone versus carfilzomib–dexamethasone in patients with relapsed multiple myeloma (IKEMA): overall survival analysis of a phase 3, randomised, controlled trial

Kwee Yong, T. John Martin, Meletios A Dimopoulos, Joseph Mıkhael, Marcelo Capra, Thierry Façon, Roman Hájek, Ivan Špıčka, Ross Baker, Kihyun Kım, Gracia Martínez, Chang‐Ki Min, Luděk Pour, Xavier Leleu, Albert Oriol, Youngil Koh, Kenshi Suzuki, France Casca, Sandrine Macé, Marie‐Laure Risse, Philippe Moreau

Article2015

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

Meletios A Dimopoulos, Philippe Moreau, Antonio Palumbo, Douglas Joshua, Luděk Pour, Roman Hájek, Thierry Façon, Heinz Ludwig, Albert Oriol, Hartmut Goldschmidt, Laura Rosiñol, Jan Štraub, Aleksandr Suvorov, Carla Araujo, Elena Rimashevskaya, Tomáš Pika, Gianluca Gaïdano, Katja Weisel, Vesselina Goranova‐Marinova, Anthony P. Schwarer, Leonard Minuk,

Article2023

Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study

Thomas G. Martin, Meletios A Dimopoulos, Joseph Mıkhael, Kwee Yong, Marcelo Capra, Thierry Façon, Roman Hájek, Ivan Špıčka, Ross Baker, Kihyun Kım, Gracia Martínez, Chang‐Ki Min, Luděk Pour, Xavier Leleu, Albert Oriol, Youngil Koh, Kenshi Suzuki, France Casca, Sandrine Macé, Marie‐Laure Risse, Philippe Moreau